Janssen Research & Development

Part of Johnson & Johnson

CompanyUnited StatesFounded 2001

ROR

Janssen Research & Development develops 21 assets, the furthest approved (amivantamab in non-small cell lung cancer). Mostly small molecule and antibody acting on EGFR, MET and SLC5A2; based in the United States, founded in 2001.

21
Assets
Furthest stage
Approved
727
Trials
188
Signals

Pipeline

21
  • amivantamab

    Bispecific antibody targeting EGFR and MET, blocking signaling and promoting immune-mediated tumor cell killing.

    Approved, Antibody, EGFR, MET, non-small cell lung cancer, locally advanced or metastatic non small cell lung cancer

  • canagliflozin

    Fixed-dose combination of DPP-4 inhibitor teneligliptin and SGLT2 inhibitor canagliflozin to improve glycemic control

    Approved, Small molecule, SLC5A2, type 2 diabetes, diabetic kidney disease

  • daratumumab

    Anti-CD38 monoclonal antibody inducing targeted immune-mediated lysis of CD38-expressing cells.

    Approved, Antibody, CD38, multiple myeloma, newly diagnosed multiple myeloma

18 more assets

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms11
  • Trials826
  • Signals20
  • Integrity notices4
  • Similar companies6

Papers

Intelligence